Markets
Still life of Ozempic and Wegovy with weight scale.
(Michael Siluk/Getty Images)

Hims slips after market despite earnings, revenue beat

The company reported that it has 2.37 million subscribers, up 38% year over year but less than the 2.42 million analysts expected.

Hims & Hers whipsawed in after-hours trading despite reporting earnings results for the first three months of the year that blew Wall Street expectations out of the park.

It reported earnings per share of $0.20, compared to the $0.12 analysts polled by FactSet were expecting. The company also reported $586 million in sales, up 111% year over year, far higher than the $538.6 million analysts polled by FactSet were penciling in. Hims & Hers reiterated its full-year revenue guidance of $2.3 billion to $2.4 billion, which is in line with analysts’ consensus.

The company did report that it has 2.37 million subscribers, up 38% year over year but less than the 2.42 million analysts expected. It also said it expects to make between $530 million to $550 million in revenue in the second quarter of this year, less than the $564 million the Street was hoping for.

Both estimates would mark a quarter-over-quarter decline in revenue, a first for Hims since it went public in 2020.

Hims did not specify in the report how much revenue it made from its weight-loss segment. This is the last full quarter where the company will be able to continue selling compounded semaglutide, the active ingredient in Novo Nordisks blockbuster weight-loss drugs, Ozempic and Wegovy. The FDA declared in February that semaglutide is no longer in shortage, and the deadline for Hims to stop selling copies of the drug is May 22.

Investors have been hungry for details on what Hims weight-loss business will look like moving forward. Novo Nordisk announced a partnership Hims and two other telehealth companies last week. Hims users will now be able to access branded semaglutide through the platform, though its unclear what kind of margins that gives the company.

Hims has said that it will continue offering personalized GLP-1 drugs, which it says doesnt skirt the FDAs regulations. According to the company, more than half of its total subscribers are on some form of personalized medication, though its unclear what the figure is for those on semaglutide specifically.

In its shareholder letter, Hims said that it would expand into hormone-related categories like low testosterone and menopause by the end of the year. Hims, which currently also said it would pursue international expansion through organic growth and opportunistic M&A over the course of the next five years.

Hims announced earlier on Monday that Nader Kabbani, a longtime Amazon executive who most recently worked at the robotics company Symbiotic, would serve as its next chief operating officer. He is replacing Melissa Baird, a longtime executive who joined Hims shortly after it was founded.

More Markets

See all Markets
markets

SpaceX gets a wave of bullish ratings from Wall Street analysts

SpaceX received more than a dozen positive analyst calls on Tuesday — including from major Wall Street banks — as they initiate coverage on Elon Musk’s space and AI company.

SpaceX went public on June 12 at a $2.2 trillion valuation, the largest debut in history. While the company hasn’t yet posted a profit, it seems to have convinced Wall Street that it will get there and grow its valuation on the way.

Of the at least 17 analysts that gave a rating on Tuesday, all but one gave it a “buy” or “outperform” rating. MoffettNathanson was "neutral."

The ratings come as SpaceX joined the Nasdaq 100 index, a benchmark tech-heavy basket of companies that underpins millions of portfolios. The inclusion adds built-in demand for the stock from index funds and ETFs.

Still, SpaceX fell more than 5% on Tuesday amid a broader sell-off, and is currently effectively flat from its opening price of $150 a share.

markets

Nike sinks to lowest level since 2014 after warning of “challenged” sales environment in Q4 report

Did Nike do it?

Investors had a mixed reaction after the global sports apparel company reported its fourth quarter earnings on Tuesday after the bell. Shares initially rose 5% as Nike beat out Wall Street expectations amid a hefty tariff refund bonus. However, the stock then sank to its lowest level since August 2014 in postmarket trading.

Here are the Q4 numbers:

  • Revenue of $11.0 billion (estimate: $10.8 billion).

  • Adjusted earnings per share of $0.20 (estimate: $0.12).

Ahead of this report, Nike warned that results would be flattered by a one-time tariff refund (now estimated at roughly $0.52 per share for the bottom line). That gave the company an extra cushion in snapping its streak of seven quarters of year-over-year profit declines.

Over the past year, the company had been punished by tariffs on imported goods, stagnant consumer spending, and increasing competition from other footwear brands like New Balance, Adidas, and Hoka.

Outgoing CFO Matthew Friend deemed it an “increasingly challenging operating environment, where sell-through remains challenged.”

markets

Rocket Lab deal lifts space stocks

Shares of Rocket Lab are surging after announcing an $8 billion acquisition of satellite communications operator Iridium Communications, helping lift a broader basket of space-related stocks as investors piled back into the sector.

Planet Labs, AST SpaceMobile and Redwire all traded higher alongside Rocket Lab, extending gains in an industry that has drawn enhanced investor attention in recent months in light of the strategic importance that governments place on space and satellite communications infrastructure.

In a presentation, Rocket Lab’s management called the purchase “a shortcut” for its satellite communications business.

Under the terms of the agreement, Iridium shareholders will receive $27 in cash and Rocket Lab stock, valuing Iridium at $54 per share. Backed by a $3.6 billion bridge loan committed by Deutsche Bank and Wells Fargo, Rocket Lab absorbs Iridium’s globally licensed spectrum and an active base of 2.5 million subscribers.

Rocket Lab has also remained one of the most active launch providers in the sector. The company completed its 12th launch of the year last week, maintaining one of the highest launch cadences among commercial space companies.

Today's rally helps offset a brutal stretch for the group. Rocket Lab shares had fallen over 35% over the prior month, while Planet Labs stock was down more than 40% and AST SpaceMobile stock was down around 30% over the same window.

Latest Stories

Sherwood Media, LLC and Chartr Limited produce fresh and unique perspectives on topical financial news and are fully owned subsidiaries of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Money, LLC, Robinhood U.K. Ltd, Robinhood Derivatives, LLC, Robinhood Gold, LLC, Robinhood Asset Management, LLC, Robinhood Credit, Inc., Robinhood Ventures DE, LLC and, where applicable, its managed investment vehicles.